Share Twitter LinkedIn Facebook Email Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Center Discusses B-Cell Maturation Antigen (BCMA): Many Trials Using This Marker As A Target, Bispecific Antibodies Target This Marker.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read